NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
59651-113-05 | 59651-113 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 40 mg/1 | 500 TABLET in 1 BOTTLE (59651-113-05) |
59651-113-30 | 59651-113 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 40 mg/1 | 30 TABLET in 1 BOTTLE (59651-113-30) |
59651-113-90 | 59651-113 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 40 mg/1 | 90 TABLET in 1 BOTTLE (59651-113-90) |
59651-114-01 | 59651-114 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 80 mg/1 | 100 TABLET in 1 BOTTLE (59651-114-01) |
59651-114-05 | 59651-114 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 80 mg/1 | 500 TABLET in 1 BOTTLE (59651-114-05) |
59651-114-30 | 59651-114 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 80 mg/1 | 30 TABLET in 1 BOTTLE (59651-114-30) |
59651-114-90 | 59651-114 | HUMAN PRESCRIPTION DRUG | Febuxostat | Febuxostat | TABLET | ORAL | 20231025 | N/A | ANDA | ANDA210741 | Aurobindo Pharma Limited | FEBUXOSTAT | 80 mg/1 | 90 TABLET in 1 BOTTLE (59651-114-90) |